RXi Pharmaceuticals Corp. (RXII)

2.16
0.04 1.89
NASDAQ : Health Technology
Prev Close 2.12
Open 2.15
Day Low/High 2.11 / 2.18
52 Wk Low/High 1.90 / 7.70
Volume 82.38K
Avg Volume 289.00K
Exchange NASDAQ
Shares Outstanding 4.26M
Market Cap 9.53M
EPS -5.50
P/E Ratio N/A
Div & Yield N.A. (N.A)
RXi Pharmaceuticals To Webcast Presentation At The 13th Annual BIO CEO & Investor Conference

RXi Pharmaceuticals To Webcast Presentation At The 13th Annual BIO CEO & Investor Conference

RXi Pharmaceuticals Corporation (Nasdaq: RXII), a recognized leader in RNAi-based therapeutic discovery and development, today announced that the Company’s President and Chief Executive Officer, Noah D.

RXi Pharmaceuticals Initiates Development Program For Dermal Anti-Scarring Product Candidate

RXi Pharmaceuticals Initiates Development Program For Dermal Anti-Scarring Product Candidate

RXi Pharmaceuticals Corporation (Nasdaq: RXII), a recognized leader in RNAi-based therapeutic discovery and development, today announced further details regarding RXI-109, the company’s dermal anti-scarring ...

RXi Pharmaceuticals Announces Positive Initial Results In MicroRNA Therapeutics

RXi Pharmaceuticals Announces Positive Initial Results In MicroRNA Therapeutics

RXi Pharmaceuticals Corporation (Nasdaq: RXII), a recognized leader in RNAi-based therapeutics, announced today that, as part of its collaboration with miRagen Therapeutics, Inc.

RXi Pharmaceuticals To Webcast Presentation At The Biotech Showcase Conference

RXi Pharmaceuticals To Webcast Presentation At The Biotech Showcase Conference

RXi Pharmaceuticals Corporation (Nasdaq: RXII), a recognized leader in RNAi-based therapeutic discovery and development, today announced that the Company’s President and Chief Executive Officer, Noah D.

RXi Pharmaceuticals Nominates Dermal Anti-Scarring RNAi Product Candidate To Advance Into Development

RXi Pharmaceuticals Nominates Dermal Anti-Scarring RNAi Product Candidate To Advance Into Development

RXi Pharmaceuticals Corporation (Nasdaq: RXII), a recognized leader in RNAi-based therapeutic discovery and development, today announced the selection of its first RNAi therapeutic product candidate to advance into...

RXi Pharmaceuticals Reports Financial Results For The Third Quarter Of 2010

RXi Pharmaceuticals Reports Financial Results For The Third Quarter Of 2010

RXi Pharmaceuticals Corporation (Nasdaq: RXII), a recognized leader in RNAi-based therapeutic discovery and development, today reported its financial results for the third quarter ended September 30, 2010.

RXi Pharmaceuticals To Webcast Presentation At The Lazard Capital Markets Annual Healthcare Conference

RXi Pharmaceuticals To Webcast Presentation At The Lazard Capital Markets Annual Healthcare Conference

RXi Pharmaceuticals Corporation (Nasdaq: RXII), a recognized leader in RNAi-based therapeutic discovery and development, today announced that the Company’s President and Chief Executive Officer, Noah D.

RXi Pharmaceuticals Awarded $1 Million In IRS Grants To Advance RNAi Therapeutics

RXi Pharmaceuticals Corporation (Nasdaq: RXII), a recognized leader in RNAi-based therapeutic discovery and development, today announced that it was awarded four Therapeutic Discovery Project (TDP) grants, totaling ...

RXi Pharmaceuticals To Webcast Presentation At The 9th Annual BIO Investor Forum

RXi Pharmaceuticals Corporation (Nasdaq: RXII), a recognized leader in RNAi-based therapeutic discovery and development, today announced that the Company’s President and Chief Executive Officer, Noah D.

RXi Pharmaceuticals And EyeGate Pharma Announce Collaboration Focused On Non-Invasive Ocular Delivery Of RNAi Therapeutics

RXi Pharmaceuticals Corporation (Nasdaq: RXII), a recognized leader in RNAi-based therapeutics, and EyeGate Pharma, the leader in non-invasive ocular drug delivery announced today that they will collaborate on the ...

Rodman Rambles: Promising Biotechs

Rodman Rambles: Promising Biotechs

This week's Rodman investor confab included some small, early biotechs worthy of investor attention.

RXi Pharmaceuticals To Webcast Presentation At The Rodman & Renshaw Global Investment Conference

RXi Pharmaceuticals Corporation (Nasdaq: RXII), a recognized leader in RNAi-based therapeutic discovery and development, today announced that the Company’s President and Chief Executive Officer, Noah D.

RXi Pharmaceuticals Reports Financial Results For The Second Quarter Of 2010

RXi Pharmaceuticals Corporation (Nasdaq: RXII), a recognized leader in RNAi-based therapeutic discovery and development, today reported its financial results for the second quarter ended June 30, 2010.

RXi Pharmaceuticals To Host Second Quarter 2010 Conference Call On Wednesday, August 11, 2010

RXi Pharmaceuticals Corporation (Nasdaq: RXII), a recognized leader in RNAi-based therapeutic discovery and development, today announced that it will release financial results for the quarter ended June 30, 2010 on ...

RXi Pharmaceuticals Receives $600,000 Grant

RXi Pharmaceuticals Receives $600,000 Grant

RXi Pharmaceuticals receives $600,000 federal grant for gene-silencing technology

RXi Pharmaceuticals Awarded NIH Grant To Advance RNAi Therapeutics

RXi Pharmaceuticals Awarded NIH Grant To Advance RNAi Therapeutics

RXi Pharmaceuticals Corporation (Nasdaq: RXII), a recognized leader in RNAi-based therapeutic discovery and development, today announced that it was awarded an Advanced Technology Small Business Innovation Research ...

RXi Pharmaceuticals Announces New Focused Therapeutic Strategy For Its Next Generation RNAi Technology

RXi Pharmaceuticals Corporation (Nasdaq: RXII), a recognized leader in RNAi-based therapeutic discovery and development, today announced the company’s new focused RNAi therapeutic strategy at the Jefferies 2010 ...

Philips And RXi Pharmaceuticals Sign Agreement To Jointly Research Innovative Image-Guided Therapy Concepts Based On RNAi

Royal Philips Electronics (NYSE: PHG, AEX: PHI) and RXi Pharmaceuticals Corporation (Nasdaq: RXII), a US-based biopharmaceutical company, today announced that they have entered into a joint research agreement to...

RXi Pharmaceuticals CEO To Present At The Jefferies 2010 Global Life Sciences Conference

RXi Pharmaceuticals Corporation (Nasdaq: RXII), a recognized leader in RNAi-based therapeutic discovery and development, today announced that the Company's President and Chief Executive Officer, Noah D.

RXi Pharmaceuticals Reports Financial Results For The First Quarter Of 2010

RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today reported its financial...

RXi Pharmaceuticals CEO To Present At The Rodman & Renshaw Annual Global Healthcare Conference

RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that the ...

RXi Demonstrates Robust In Vivo Uptake And Significant Silencing Using Its Self-Delivering RxRNA™ Compounds Administered To Mouse Retinal Cells

RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced new preclinical...

RXi Pharmaceuticals To Deliver Presentations At Upcoming Conferences Outlining The Development And Progression Of Its Next Generation RxRNA™ Therapeutic Platform

RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that senior...

RXi Pharmaceuticals Presents At AACR Conference, Highlighting The Potential For RNAi Therapeutics In Oncology

RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that Anastasia...

RXi Pharmaceuticals And MiRagen Therapeutics Announce Formation Of Research Collaboration In The Field Of MicroRNA

RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), and miRagen Therapeutics, Inc.

RXi Pharmaceuticals Announces Formation Of MicroRNA Research Collaboration With Mirna Therapeutics

RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), announced today that it has...

RXi Pharmaceuticals And TransDerm Announce Formation Of Research Collaboration

RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), and TransDerm, Inc.

RXi Pharmaceuticals CEO To Present At The Future Leaders In The Biotech Industry Investment Conference

RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that the ...

7 Firms Developing RNAi Drugs

7 Firms Developing RNAi Drugs

Biotech investors are paying close attention to RNAi. Here are seven drug and biotech companies focused on developing RNAi drugs.

RXi Pharmaceuticals To Host Year-End 2009 Earnings Conference Call And Webcast On Wednesday, March 31, 2010

RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that its ...

TheStreet Quant Rating: E+ (Sell)